Patients Discontinuing Weight-Loss Jabs Regain Weight Far More Rapidly Compared to People Using Diet and Exercise

A recent study indicates that individuals who stop using new slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional lifestyle plans.

Research printed in a major health publication shows that while overweight people often shed about a fifth of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.

"Individuals purchasing these medications need to be aware of the potential of quick rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.

Such speed of regain means a reversion to pre-treatment mass in about 18 months.

Weighing Treatments

The analysis, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.

The team emphasize that individuals who shed pounds through lifestyle changes alone usually have a less rapid creep back—around 100 grams monthly—after stopping.

Explaining the Rapid Regain

Nutrition scientists suggest the way of the jabs explains the accelerated regain.

These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this hormone supplement results in appetite is no longer kept in check, making binge eating a significant risk."

An Ongoing Condition?

Health authorities advise the jabs for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.

Many experts contend that, due to the significant potential of relapse, the treatment might need to be long-term.

This perspective is reinforced by drug manufacturers, who state that the findings "highlight the persistent character of excess weight," similar to managing conditions like hypertension.

User Accounts

People who have stopped the medication report a powerful return of cravings.

"I experienced a trigger activating and I was suddenly extremely hungry," said an individual.

This challenge is compounded if patients have not adopted permanent dietary or behavioural modifications during therapy.

Significant Interest

Figures show that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.

• Adoption is more common among women than men.
• The 40s and 50s age group shows the greatest level of interest.
• Many obtain the drugs through private prescriptions rather than public health services.

Ultimately, researchers stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and maintained weight loss relies on ongoing behavioural changes.